Pharmacological Restriction of Genomic Binding Sites Redirects PU.1 Pioneer Transcription Factor Activity
Open accessAbstract
Transcription factor (TF) DNA-binding dynamics govern cell fate and identity. However, our ability to pharmacologically control TF localization is limited. Here we leverage chemically driven binding site restriction leading to robust and DNA-sequence-specific redistribution of PU.1, a pioneer TF pertinent to many hematopoietic malignancies. Through an innovative technique, 'CLICK-on-CUT&Tag', we characterize the hierarchy of de novo PU.1 motifs, predicting occupancy in the PU.1 cistrome under binding site restriction. Temporal and single-molecule studies of binding site restriction uncover the pioneering dynamics of native PU.1 and identify the paradoxical activation of an alternate target gene set driven by PU.1 localization to second-tier binding sites. These transcriptional changes were corroborated by genetic blockade and site-specific reporter assays. Binding site restriction and subsequent PU.1 network rewiring causes primary human leukemia cells to differentiate. In summary, pharmacologically induced TF redistribution can be harnessed to govern TF localization, actuate alternate gene networks and direct cell fate.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PU.1 binds specific DNA sequences known as ETS motifs, which are located predominantly in enhancers but also in promoters of target genes.
“PU.1, as an ETS family transcription factor, binds specific DNA sequences known as ETS motifs, which are located predominantly in the enhancers but also in the promoters of target genes [30, 31].”
From Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease (2026) · cites this paper as [30]
The Results section (‘Pharmacological binding site restriction repositions PU.1’; page unavailable) reports enrichment of ETS motifs at PU.1 binding sites and identifies some sites in promoter regions. It does not establish that PU.1 binding sites are predominantly in enhancers, so that part of the claim is unsupported by our copy. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · see citing works
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · see citing works
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807 · see citing works
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382 · see citing works
Enrichr: a comprehensive gene set enrichment analysis web server 2016 update
Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z., Koplev, S., Jenkins, S. L., Jagodnik, K. M., Lachmann, A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw377 · Cited by 10,799 · see citing works
Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
Chen, E. Y., Tan, C. M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G. V., Clark, N. R., & Ma’ayan, A. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-128 · Cited by 7,814 · see citing works
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422 · see citing works
Fast gene set enrichment analysisPreprint
Korotkevich, G., Sukhov, V., Budin, N., Shpak, B., Artyomov, M. N., & Sergushichev, A. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/060012 · Cited by 3,742 · see citing works
Gene set knowledge discovery with enrichr
Xie, Z., Bailey, A., Kuleshov, M. V., Clarke, D. J. B., Evangelista, J. E., Jenkins, S. L., Lachmann, A., Wojciechowicz, M. L., Kropiwnicki, E., Jagodnik, K. M., et al. (2021) · Current Protocols · doi:10.1002/cpz1.90 · Cited by 3,451 · see citing works
The Human Transcription Factors
Lambert, S. A., Jolma, A., Campitelli, L. F., Das, P. K., Yin, Y., Albu, M., Chen, X., Taipale, J., Hughes, T. R., & Weirauch, M. T. (2018) · Cell · doi:10.1016/j.cell.2018.01.029 · Cited by 3,399 · see citing works
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395 · see citing works
The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773 · see citing works
An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues
Corces, M. R., Trevino, A. E., Hamilton, E. G., Greenside, P. G., Sinnott-Armstrong, N. A., Vesuna, S., Satpathy, A. T., Rubin, A. J., Montine, K. S., Wu, B., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4396 · Cited by 2,496 · see citing works
Cui, P., Zhang, S., Ding, F. H., Ali, S., & Xiong, L. (2014) · Genome biology · doi:10.1186/gb-2014-15-1-r1 · Cited by 2,282 · see citing works
CUT&Tag for efficient epigenomic profiling of small samples and single cells
Kaya-Okur, H. S., Wu, S. J., Codomo, C. A., Pledger, E. S., Bryson, T. D., Henikoff, J. G., Ahmad, K., & Henikoff, S. (2019) · Nature Communications · doi:10.1038/s41467-019-09982-5 · Cited by 2,187 · see citing works
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
Scott, E. W., Simon, M. C., Anastasi, J., & Singh, H. (1994) · Science · doi:10.1126/science.8079170 · Cited by 1,532 · see citing works
Corces, M. R., Buenrostro, J. D., Wu, B., Greenside, P. G., Chan, S. M., Koenig, J. L., Snyder, M. P., Pritchard, J. K., Kundaje, A., Greenleaf, W. J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3646 · Cited by 1,151 · see citing works
Tzelepis, K., Koike-Yusa, H., De Braekeleer, E., Li, Y., Metzakopian, E., Dovey, O. M., Mupo, A., Grinkevich, V., Li, M., Mazan, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.079 · Cited by 761 · see citing works
Ghisletti, S., Barozzi, I., Mietton, F., Polletti, S., De Santa, F., Venturini, E., Gregory, L., Lonie, L., Chew, A., Wei, C.-L., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.02.008 · Cited by 666 · see citing works
Rekhtman, N., Radparvar, F., Evans, T., & Skoultchi, A. I. (1999) · Genes & Development · doi:10.1101/gad.13.11.1398 · Cited by 454 · see citing works
Bancaud, A., Huet, S., Daigle, N., Mozziconacci, J., Beaudouin, J., & Ellenberg, J. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.340 · Cited by 438 · see citing works
Advances in Targeting ‘Undruggable’ transcription Factors With Small Molecules
Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409 · see citing works
PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding
Zhang, P., Zhang, X., Iwama, A., Yu, C., Smith, K. A., Mueller, B. U., Narravula, S., Torbett, B. E., Orkin, S. H., & Tenen, D. G. (2000) · Blood · doi:10.1182/blood.v96.8.2641 · Cited by 368 · see citing works
Mizuki, M., Schwäble, J., Steur, C., Choudhary, C., Agrawal, S., Sargin, B., Steffen, B., Matsumura, I., Kanakura, Y., Böhmer, F. D., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1677 · Cited by 298 · see citing works
Hohaus, S., Petrovick, M. S., Voso, M. T., Sun, Z., Zhang, D.-E., & Tenen, D. G. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.10.5830 · Cited by 284 · see citing works
Nucleophilic Aryl Fluorination and Aryl Halide Exchange Mediated by a CuI/CuIII Catalytic Cycle
Casitas, A., Canta, M., Solà, M., Costas, M., & Ribas, X. (2011) · Journal of the American Chemical Society · doi:10.1021/ja2058567 · Cited by 262 · see citing works
Vangala, R. K., Heiss-Neumann, M. S., Rangatia, J. S., Singh, S. M., Schoch, C., Tenen, D. G., Hiddemann, W., & Behre, G. (2003) · Blood · doi:10.1182/blood-2002-04-1288 · Cited by 245 · see citing works
Heterozygous PU.1 mutations are associated with acute myeloid leukemia
Mueller, B. U., Pabst, T., Osato, M., Asou, N., Johansen, L. M., Minden, M. D., Behre, G., Hiddemann, W., Ito, Y., & Tenen, D. G. (2002) · Blood · doi:10.1182/blood.v100.3.998 · Cited by 243 · see citing works
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia
Kühn, M. W. M., Song, E. J., Feng, Z.-H., Sinha, A., Chen, C., Deshpande, A., Cusan, M., Farnoud, N., Mupo, A., Grove, C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0237 · Cited by 241 · see citing works
Xu, B., On, D. M., Ma, A., Parton, T., Konze, K. D., Pattenden, S. G., Allison, D. F., Cai, L., Rockowitz, S., Liu, S., et al. (2014) · Blood · doi:10.1182/blood-2014-06-581082 · Cited by 229 · see citing works
Barozzi, I., Simonatto, M., Bonifacio, S., Yang, L., Rohs, R., Ghisletti, S., & Natoli, G. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.04.006 · Cited by 209 · see citing works
FISH-quant v2: a scalable and modular tool for smFISH image analysis
Imbert, A., Ouyang, W., Safieddine, A., Coleno, E., Zimmer, C., Bertrand, É., Walter, T., & Mueller, F. (2022) · RNA · doi:10.1261/rna.079073.121 · Cited by 186 · see citing works
Essential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells
Steidl, U., Rosenbauer, F., Verhaak, R. G. W., Gu, X., Ebralidze, A., Otu, H. H., Klippel, S., Steidl, C., Bruns, I., Costa, D. B., et al. (2006) · Nature Genetics · doi:10.1038/ng1898 · Cited by 184 · see citing works
Self-citationTargeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
Bell, C. C., Fennell, K. A., Chan, Y.-C., Rambow, F., Yeung, M. M., Vassiliadis, D., Gonzalez, L. E. L., Yeh, P. S.-H., Martelotto, L. G., Rogiers, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10652-9 · Cited by 179 · see citing works
Fu, X., Jeselsohn, R. M., Pereira, R., Hollingsworth, E. F., Creighton, C. J., Li, F., Shea, M. J., Nardone, A., Angelis, C. D., Heiser, L. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612835113 · Cited by 167 · see citing works
Viny, A. D., Bowman, R. L., Liu, Y., Lavallée, V., Eisman, S. E., Xiao, W., Durham, B. H., Navitski, A., Park, J., Braunstein, S., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.08.003 · Cited by 163 · see citing works
Crystal structure of PU. 1/IRF-4/DNA ternary complex
Escalante, C. R., Brass, A. L., Pongubala, J. M. R., Shatova, E., Shen, L., Singh, H., & Aggarwal, A. K. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00703-7 · Cited by 154 · see citing works
Click chemistry enables preclinical evaluation of targeted epigenetic therapies
Tyler, D. S., Vappiani, J., Cañeque, T., Lam, E. Y. N., Ward, A., Gilan, O., Chan, Y.-C., Hienzsch, A., Rutkowska, A., Werner, T., et al. (2017) · Science · doi:10.1126/science.aal2066 · Cited by 146 · see citing works
Minderjahn, J., Schmidt, A., Fuchs, A., Schill, R., Raithel, J., Babina, M., Schmidl, C., Gebhard, C., Schmidhofer, S., Mendes, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13960-2 · Cited by 136 · see citing works
Immune cell-specific amplification of interferon signaling by the IRF-4/8-PU. 1 complex
Kanno, Y., Levi, B.-Z., Tamura, T., & Ozato, K. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.770 · Cited by 128 · see citing works
Will, B., Vogler, T. O., Narayanagari, S., Bartholdy, B., Todorova, T. I., da Silva Ferreira, M., Chen, J., Yu, Y., Mayer, J., Barreyro, L., et al. (2015) · Nature Medicine · doi:10.1038/nm.3936 · Cited by 127 · see citing works
Self-citationPharmacological inhibition of the transcription factor PU.1 in leukemia
Antony-Debré, I., Paul, A., Leite, J., Mitchell, K., Kim, H. M., Carvajal, L. A., Todorova, T. I., Huang, K., Kumar, A., Farahat, A. A., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92504 · Cited by 120 · see citing works
Self-citationHosokawa, H., Ungerbäck, J., Wang, X., Matsumoto, M., Nakayama, K. I., Cohen, S. M., Tanaka, T., & Rothenberg, E. V. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.024 · Cited by 116 · see citing works
Gu, X., Ebrahem, Q., Mahfouz, R. Z., Hasipek, M., Enane, F. O., Radivoyevitch, T., Rapin, N., Przychodzen, B. P., Hu, Z., Balusu, R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97117 · Cited by 114 · see citing works
Steidl, U., Steidl, C., Ebralidze, A., Chapuy, B., Han, H.-J., Will, B., Rosenbauer, F., Becker, A., Wagner, K., Koschmieder, S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30525 · Cited by 114 · see citing works
Self-citationMechanisms of in vivo binding site selection of the hematopoietic master transcription factor PU.1
Pham, T.-H., Minderjahn, J., Schmidl, C., Hoffmeister, H., Schmidhofer, S., Chen, W., Längst, G., Benner, C., & Rehli, M. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt355 · Cited by 102 · see citing works
Characterization of the myeloid-specific CD11b promoter
Pahl, H., Rosmarin, A., & Tenen, D. (1992) · Blood · doi:10.1182/blood.v79.4.865.bloodjournal794865 · Cited by 95 · see citing works
Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia
McKenzie, M. D., Ghisi, M., Oxley, E. P., Ngo, S., Cimmino, L., Esnault, C., Liu, R., Salmon, J. M., Bell, C. C., Ahmed, N., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.07.001 · Cited by 91 · see citing works
Single-molecule imaging of transcription dynamics in somatic stem cells
Wheat, J. C., Sella, Y., Willcockson, M., Skoultchi, A. I., Bergman, A., Singer, R. H., & Steidl, U. (2020) · Nature · doi:10.1038/s41586-020-2432-4 · Cited by 88 · see citing works
Self-citationTargeting LSD1 for acute myeloid leukemia (AML) treatment
Zhang, S., Liu, M., Yao, Y., Yu, B., & Liu, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105335 · Cited by 85 · see citing works
Hershberg, E. A., Camplisson, C. K., Close, J., Attar, S., Chern, R., Liu, Y., Akilesh, S., Nicovich, P. R., & Beliveau, B. J. (2021) · Nature Methods · doi:10.1038/s41592-021-01187-3 · Cited by 81 · see citing works
Specific Interactions of the Wing Domains of FOXA1 Transcription Factor with DNA
Cirillo, L. A., & Zaret, K. S. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.11.087 · Cited by 79 · see citing works
Ungerbäck, J., Hosokawa, H., Wang, X., Strid, T., Williams, B. A., Sigvardsson, M., & Rothenberg, E. V. (2018) · Genome Research · doi:10.1101/gr.231423.117 · Cited by 77 · see citing works
Nascent RNA sequencing analysis provides insights into enhancer-mediated gene regulation
Wang, J., Zhao, Y., Zhou, X., Hiebert, S. W., Liu, Q., & Shyr, Y. (2018) · BMC Genomics · doi:10.1186/s12864-018-5016-z · Cited by 72 · see citing works
Zhao, Y., Liu, Q., Acharya, P., Stengel, K. R., Sheng, Q., Zhou, X., Kwak, H., Fischer, M. A., Bradner, J. E., Strickland, S. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.032 · Cited by 69 · see citing works
Self-citationMunde, M., Wang, S., Kumar, A., Stephens, C. E., Farahat, A. A., Boykin, D. W., Wilson, W. D., & Poon, G. M. K. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt955 · Cited by 68 · see citing works
Self-citationReversible Disruption of Specific Transcription Factor-DNA Interactions Using CRISPR/Cas9
Shariati, S. A., Dominguez, A. A., Xie, S., Wernig, M., Qi, L. S., & Skotheim, J. M. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.04.011 · Cited by 67 · see citing works
ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency
Cao, Z., Budinich, K. A., Huang, H., Ren, D., Lu, B., Zhang, Z., Chen, Q., Zhou, Y., Huang, Y., Alikarami, F., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.018 · Cited by 64 · see citing works
Targeting the Ets Binding Site of the HER2/neuPromoter with Pyrrole-Imidazole Polyamides
Chiang, S.-Y., Bürli, R. W., Benz, C. C., Gawron, L. S., Scott, G. K., Dervan, P. B., & Beerman, T. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000820200 · Cited by 56 · see citing works
Wontakal, S. N., Guo, X., Will, B., Shi, M., Raha, D., Mahajan, M. C., Weissman, S., Snyder, M., Steidl, U., Zheng, D., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001392 · Cited by 53 · see citing works
Self-citationPeixoto, P., Liu, Y., Depauw, S., Hildebrand, M., Boykin, D. W., Bailly, C., Wilson, W. D., & David‐Cordonnier, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn208 · Cited by 52 · see citing works
Self-citationPerry, J. A., Seong, B. K. A., & Stegmaier, K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055710 · Cited by 42 · see citing works
Pharmacologic efficacy of PU.1 inhibition by heterocyclic dications: a mechanistic analysis
Stephens, D. C., Kim, H. M., Kumar, A., Farahat, A. A., Boykin, D. W., & Poon, G. M. K. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw229 · Cited by 38 · see citing works
Self-citationZhang, S., Wang, J., Liu, Q., McDonald, W. H., Bomber, M. L., Layden, H. M., Ellis, J. D., Borinstein, S. C., Hiebert, S. W., & Stengel, K. R. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.10.025 · Cited by 38 · see citing works
Self-citationDesigned Compounds for Recognition of 10 Base Pairs of DNA with Two AT Binding Sites
Liu, Y., Chai, Y., Kumar, A., Tidwell, R. R., Boykin, D. W., & Wilson, W. D. (2012) · Journal of the American Chemical Society · doi:10.1021/ja211628j · Cited by 37 · see citing works
Self-citationTargeting a DNA Binding Motif of the EVI1 Protein by a Pyrrole–Imidazole Polyamide
Zhang, Y., Sicot, G., Cui, X., Vogel, M. J., Wuertzer, C. A., Lezon-Geyda, K., Wheeler, J., Harki, D. A., Muzikar, K. A., Stolper, D. A., et al. (2011) · Biochemistry · doi:10.1021/bi200962u · Cited by 35 · see citing works
Heterozygous deletion of the PU.1 locus in human AML
Bonadies, N., Pabst, T., & Mueller, B. U. (2010) · Blood · doi:10.1182/blood-2009-03-212225 · Cited by 33 · see citing works
A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation
Ralvenius, W. T., Mungenast, A. E., Woolf, H., Huston, M. M., Gillingham, T. Z., Godin, S. K., Penney, J., Cam, H. P., Gao, F., Fernandez, C. G., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20222105 · Cited by 31 · cited 1× · see citing works
“…as it directs a well-characterized transcriptional program that governs cell fate 4,11,12 , has demonstrated proof-of-concept sensitivity to binding site inhibition, specifically compared to other ETS family TFs 8,9,13,14 , and is commonly dysregulated in leukemia and other diseases 15–26 .”
Sadoun, H. A., Burgess, M., Hentges, K. E., & Mace, K. (2016) · Journal of Immunology · doi:10.4049/jimmunol.1501944 · Cited by 31 · see citing works
Base Coupling in Sequence-specific Site Recognition by the ETS Domain of Murine PU.1
Poon, G. M. K., & Macgregor, R. B. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00362-0 · Cited by 29 · see citing works
Self-citationPoon, G. M. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.342345 · Cited by 28 · see citing works
Self-citationMunde, M. M., Poon, G. M. K., & Wilson, W. D. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.02.010 · Cited by 26 · see citing works
Self-citationPharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia
Lu, R., & Wang, G. G. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00241 · Cited by 25 · see citing works
Liu, Y., Collar, C. J., Kumar, A., Stephens, C. E., Boykin, D. W., & Wilson, W. D. (2008) · The Journal of Physical Chemistry B · doi:10.1021/jp804048c · Cited by 25 · see citing works
Self-citationSynthesis and Potent Antimicrobial Activities of Some Novel Retinoidal Monocationic Benzimidazoles
Ateş‐Alagöz, Z., Alp, M., Kuş, C., Yıldız, S., Büyükbingöl, E., & Göker, H. (2006) · Archiv der Pharmazie · doi:10.1002/ardp.200500168 · Cited by 23 · see citing works
Chemical-induced phase transition and global conformational reorganization of chromatin
Wang, T., Shi, S., Shi, Y., Jiang, P., Hu, G., Ye, Q., Shi, Z., Yu, K., Wang, C., Fan, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41340-4 · Cited by 22 · see citing works
Sive, J. I., Basilico, S., Hannah, R., Kinston, S., Calero‐Nieto, F. J., & Göttgens, B. (2015) · Leukemia · doi:10.1038/leu.2015.172 · Cited by 17 · see citing works
Xhani, S., Esaki, S., Huang, K., Erlitzki, N., & Poon, G. M. K. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b00325 · Cited by 15 · see citing works
Self-citationOgbonna, E. N., Paul, A., Terrell, J. R., Fang, Z., Chen, C., Poon, G. M. K., Boykin, D. W., & Wilson, W. D. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116861 · Cited by 11 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Hematopoietic stem and progenitor cells as a reservoir for trained immunity
Tran, B. T., Jeyanathan, V., Cao, R., Kaufmann, E., & King, K. Y. (2025) · eLife · doi:10.7554/elife.106610 · Cited by 25 · see citing works
Sun, S., Chen, Y., Ouyang, Y., & Tang, Z. (2024) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-024-09011-4 · Cited by 10 · see citing works
Beck, D., Cao, H., Tian, F., Huang, Y., Jiang, M., Zhao, H., Tai, X., Xu, W., Kosasih, H. J., Kealy, D. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54096-2 · Cited by 9 · see citing works
“54 )was used to calculate a log-odds scoreforGR-LSOs and non-GR-LSOs using theannotatedpeaksfunctionfromtheHomerpackagewiththe-mand -mscore options enabled 38 .”
Self-citationGATA2 decommissioning of enhancers: A mechanism to constrain inflammatory signaling
Jung, M. M., Tran, V. L., Xiong, Y., Johnson, K. D., Katsumura, K. R., Liu, P., & Bresnick, E. H. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116344 · Cited by 6 · see citing works
Drug targeting of protein-nucleic acid interactions
Genz, L. R., Nair, S. A., Sweeney, A., & Topf, M. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103165 · Cited by 5 · see citing works
Paul, A., Terrell, J. R., Farahat, A. A., Ogbonna, E. N., Kumar, A., Boykin, D. W., Neidle, S., & Wilson, W. D. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.4c00800 · Cited by 4 · see citing works
Self-citationKaratepe, K., de Faria, B. M., Zhang, J., Chen, X., Pinto, H. B., Fyodorov, D. V., Sefik, E., Willcockson, M. A., Flavell, R. A., Skoultchi, A. I., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2509412122 · Cited by 3 · see citing works
Sadalge, D., Clasman, J. R., Topal, S., Musser, D., Von der Porten, L., Wu, S., Schultz, S. E., Austin, W., Huang, D., Gao, Y.-D., et al. (2025) · doi:10.1101/2025.08.01.667454 · Cited by 2 · see citing works
Zhang, T., Yang, B., Li, W., Jiao, A., Zhang, X., Ge, Y., Yang, C., Zheng, R., Sun, C., Yang, X., et al. (2026) · Stem Cell Reports · doi:10.1016/j.stemcr.2026.102791 · Cited by 1 · see citing works
lncRNA Glelr modulates microglia inflammatory programs in association with PU.1
Pradhan, R., Sakib, M. S., Kaurani, L., Krueger, D. M., Peña, T., Burkhardt, S., Schütz, A., Kronenberg‐Versteeg, D., Delalle, I., Sananbenesi, F., et al. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107366 · Cited by 1 · see citing works
Thoms, J. A. I., & Pimanda, J. E. (2026) · Blood · doi:10.1182/blood.2026033252 · Cited by 1 · see citing works
Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease
Kim, B., Wang, S. S., Kim, J. R., & Kim, J. (2026) · BioEssays · doi:10.1002/bies.70186
“PU.1, as an ETS family transcription factor, binds specific DNA sequences known as ETS motifs, which are located predominantly in the enhancers but also in the promoters of target genes [30, 31].”
Pharmacologic Blockade of a Pioneer Transcription Factor
Čermáková, K., & Hodges, H. C. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-3957
Mastering fate: Redistributing a pioneer protein to rewrite leukemia's script
Huang, Y., & de Bock, C. E. (2025) · HemaSphere · doi:10.1002/hem3.70084
eNRSA: a faster and more powerful approach for nascent transcriptome analysis
Wang, J., Chen, H., Hiebert, S. W., Sheng, Q., Tansey, W. P., Shyr, Y., & Liu, Q. (2025) · GigaScience · doi:10.1093/gigascience/giaf071
Du, J., Manna, A. K., Medina-Serpas, M. A., Hughes, E. P., Bisoma, P., Evason, K. J., Young, A., Wilson, W. D., Brusko, T. M., Farahat, A. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.22.683978
Self-citationPU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockadePreprint
Yashar, W. M., Pacentine, I. V., Taherinasab, A., Nguyen, T. T., Worme, S. J., Tsuchiya, M., Lusardi, T. A., Hutchinson, C., Fillmore, T., Posso, C., et al. (2026) · bioRxiv · doi:10.64898/2026.01.20.700677
Transitory enhancement of GATA2 chromatin engagement during early erythroid differentiationPreprint
Hobbs, J. W., Taylor, S. J., Kumari, R., Haque, N., Victor, L. L., Steidl, U. U., & Coleman, R. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.05.709895
Self-citationRapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Tatsumi, G., Kumari, R., Suzuki, Y., Li, S., Scharf, R., Taylor, S. J., Sundaravel, S., Verma, A. K., Wheat, J. C., & Steidl, U. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0317
Self-citationTransitory enhancement of GATA2 chromatin engagement during early erythroid differentiationPreprint
Hobbs, J. W., Taylor, S. J., Kumari, R., Haque, N., Victor, L. L., Steidl, U., & Coleman, R. A. (2026) · eLife · doi:10.7554/elife.111233.1
Self-citationTransitory enhancement of GATA2 chromatin engagement during early erythroid differentiationPreprint
Hobbs, J. W., Taylor, S. J., Kumari, R., Haque, N., Victor, L. L., Steidl, U., & Coleman, R. A. (2026) · eLife · doi:10.7554/elife.111233
Self-citationRamani, M., Nguyen, N., Solis, J., Tenen, D. G., & Trinh, B. Q. (2026) · Biology · doi:10.3390/biology15181657
BCLAF1 and responses to RAG-induced DNA breaks enforce pre-B cell checkpoint
Schmidt, H., Yang, W., Crowley, S. J., White, L. S., Russell, L., Zhang, R., Tran, T., Kolicheski, A., Taylor, S. J., Chen, B.-R., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.118197
Self-citation
- Authors
- Taylor, S. J., Stauber, J., Bohorquez, O., Tatsumi, G., Kumari, R., Chakraborty, J., Bartholdy, B. A., Schwenger, E., Sundaravel, S., Farahat, A. A., Wheat, J. C., Goldfinger, M., Verma, A., Kumar, A., Boykin, D. W., Stengel, K. R., Poon, G. M. K., & Steidl, U.
- Affiliations
- Albert Einstein College of Medicine (US)
- Mansoura University (EG)
- Georgia State University (US)
- Corresponding author
- Steidl, Ulrich
- ORCID
- Venue
- Nature Genetics
- Published
- 2024-09-18
- Volume
- 56
- Issue
- 10
- Pages
- 2213-2227
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC11525197
- OpenAlex
- W4402634386
- Cited by
- 22
- References
- 80
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 3
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature Genetics (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA253127)
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL155178)
- National Science Foundation (MCB2028902)
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM142213)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- PU.1, pioneer transcription factors, transcription factor-DNA binding, cistrome, leukemia cell differentiation, hematologic malignancies, transcription factor localization, cell fate
- MeSH terms
- Proto-Oncogene Protein Spi-1, Binding Sites, Cell Differentiation, Humans, Protein Binding, Proto-Oncogene Proteins, Transcription Factors, Trans-Activators, Gene Regulatory Networks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
